NCT04615013 - NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions

Cervical Esophagus AdenocarcinomaClinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Gastroesophageal Junction AdenocarcinomaPathologic Stage II Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8Pathologic Stage III Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8Thoracic Esophagus Adenocarcinoma

Interventions

DRUG

Capecitabine

Not applicable to this study

DRUG

Carboplatin

Not applicable to this study

DRUG

Docetaxel

Not applicable to this study

DRUG

Fluorouracil

Not applicable to this study

OTHER

Hafnium Oxide-containing Nanoparticles NBTXR3

Given IT or IN

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

DRUG

Leucovorin

Not applicable to this study

DRUG

Oxaliplatin

Not applicable to this study

DRUG

Paclitaxel

Not applicable to this study

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER